These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 10335865)

  • 1. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro.
    Panther LA; Coombs RW; Aung SA; dela Rosa C; Gretch D; Corey L
    J Med Virol; 1999 Jun; 58(2):165-73. PubMed ID: 10335865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.
    Steinkasserer A; Harrison R; Billich A; Hammerschmid F; Werner G; Wolff B; Peichl P; Palfi G; Schnitzel W; Mlynar E
    J Virol; 1995 Feb; 69(2):814-24. PubMed ID: 7815548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased number of single-LTR HIV-1 DNA junctions correlates with HIV-1 antigen expression and CD4+ cell decline in vivo.
    Jurriaans S; de Ronde A; Dekker J; Cornelissen M; Goudsmit J
    J Med Virol; 1995 Jan; 45(1):91-8. PubMed ID: 7714497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro.
    Moussazadeh M; Hua J; Sidhu MK; Zhao XX; Fitzgibbon JE; Liao MJ; Rashidbaigi A
    Antiviral Res; 1999 Jul; 42(3):177-87. PubMed ID: 10443530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of unintegrated forms of proviral DNA in HIV infections].
    Gashnikova NM; Pyasek A; Iagudin BI; Mamaeva OA; Pokrovskiĭ AG
    Vestn Ross Akad Med Nauk; 1998; (3):13-7. PubMed ID: 9608270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An HIV-1 protease screening assay using a non-infectious proviral clone.
    Heldsinger AA; Antonucci T
    J Virol Methods; 1994 Oct; 49(3):247-55. PubMed ID: 7868643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
    Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
    J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different kinetics of viral replication and DNA integration in the main HIV-1 cellular reservoirs in the presence and absence of integrase inhibitors.
    Surdo M; Cortese MF; Orlandi C; Di Santo F; Aquaro S; Magnani M; Perno CF; Casabianca A; Ceccherini-Silberstein F
    Antiviral Res; 2018 Dec; 160():165-174. PubMed ID: 30420339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells.
    Hyun TS; Subramanian C; Cotter MA; Thomas RA; Robertson ES
    J Virol; 2001 Sep; 75(18):8761-71. PubMed ID: 11507221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
    Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
    Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abortive infection in HeLaCD4 cells by a primary HIV type 1 isolate: implications for differential host cell tropism.
    Smyth RJ; Yi Y; Kim FM; Collman RG
    AIDS Res Hum Retroviruses; 1997 Jun; 13(9):759-69. PubMed ID: 9171220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HIV-1 expression by HIV-2.
    Rappaport J; Arya SK; Richardson MW; Baier-Bitterlich G; Klotman PE
    J Mol Med (Berl); 1995 Dec; 73(12):583-9. PubMed ID: 8825754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional effects of superinfection in HIV chronically infected T cells: studies in dually infected clones.
    Kim JH; McLinden RJ; Mosca JD; Burke DS; Boswell RN; Birx DL; Redfield RR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(4):329-42. PubMed ID: 8673541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro.
    Merrill DP; Manion DJ; Chou TC; Hirsch MS
    J Infect Dis; 1997 Jul; 176(1):265-8. PubMed ID: 9207379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.
    Jacobsen H; Ahlborn-Laake L; Gugel R; Mous J
    J Virol; 1992 Aug; 66(8):5087-91. PubMed ID: 1378515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of the effect of temporary removal of HIV drug pressure.
    Witvrouw M; Pannecouque C; Desmyter J; De Clercq E; Andries K
    Antiviral Res; 2000 Jun; 46(3):215-21. PubMed ID: 10867159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-alpha with AZT.
    Biswas DK; Mhashilkar AM; Ewaniuk DS; Pezza JA; Oh LM; Kannangara GS; Tius MA; Pardee AB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):426-34. PubMed ID: 9715838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
    Mayers DL
    Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.